Association of serum and salivary dipeptidyl peptidase-4 (DPP-4) with oral cancerous and precancerous lesions; an observational diagnostic accuracy study

被引:0
|
作者
Abdel Fattah Tarrad, Nayroz [1 ]
Gamil Shaker, Olfat [2 ]
Abdelkawy, Maha [3 ]
Hassan, Sandy [4 ]
机构
[1] Fayoum Univ, Fac Dent, Oral Med & Periodontol Dept, Faiyum, Egypt
[2] Cairo Univ, Fac Med, Med Biochem & Mol Biol Dept, Cairo, Egypt
[3] Beni Suef Univ, Fac Dent, Oral Med & Periodontol Dept, Bani Suwayf, Egypt
[4] Fayoum & Ahram Candian Univ, Fac Dent, Oral Med & Periodontol Dept, Cairo, Egypt
来源
BMC ORAL HEALTH | 2024年 / 24卷 / 01期
关键词
Oral cancer; Saliva; Serum; Dipeptidyl peptidase; Oral potentially malignant lesions; MALIGNANT-TRANSFORMATION; LICHEN-PLANUS; THERAPEUTIC TARGET; IV; RISK; EPIDEMIOLOGY; EXPRESSION; DISORDERS; DYSPLASIA; DISEASE;
D O I
10.1186/s12903-024-04939-7
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
BackgroundEnhancing the prognosis and treatment outcomes of oral cancer relies heavily on its early detection. This study aims to establish a connection between serum and salivary dipeptidyl peptidase-4 (DPP-4) levels and oral squamous cell carcinoma (OSCC), comparing them with oral potentially malignant lesions (OPMLs) and control subjects and validating salivary DPP-4 as a diagnostic marker for the early detection of oral cancer.MethodologyForty-five systemically healthy individuals were categorized into three groups: Group I consisted of 15 patients diagnosed with OSCC, Group II comprised 15 patients with OPMLs (including leukoplakia and oral lichen planus), and Group III included 15 participants without any oral mucosal lesions. Serum and whole unstimulated salivary samples were collected from all participants to assess DPP-4 levels using an enzyme-linked immunosorbent assay (ELISA) kit. Receiver operating characteristic (ROC) analysis was conducted to determine the area under the curve (AUC), sensitivity, specificity, and diagnostic accuracy of DPP-4.ResultsBoth serum and salivary DPP-4 levels were highest in the healthy group, followed by OPMLs, and lowest in the OSCC group, with statistically significant differences observed. ROC analysis demonstrated excellent diagnostic accuracy of salivary DPP-4 in distinguishing OSCC from healthy individuals, OPMLs from healthy individuals, and OSCC from OPMLs, with accuracies of 100%, 100%, and 96.67%, respectively. Salivary DPP-4 levels also exhibited a statistically significant correlation with OSCC grades.ConclusionsDPP-4 appears to play a protective, anti-oncogenic role in maintaining oral tissue health. The remarkable diagnostic accuracy of both serum and salivary DPP-4 in discriminating between OSCC, OPMLs, and healthy controls suggests its potential utility as a well-established marker for early oral cancer diagnosis. Salivary DPP-4, being non-invasive, could serve as a convenient chair-side diagnostic tool for the early detection of OSCC.Clinical trial registrationThe study was retrospectively registered on clinicaltrial.gov with NCT06087042, date of registration (first posted date): 17/10/2023
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review
    Reghunath, Swetha R.
    Rashid, Muhammed
    Chandran, Viji Pulikkel
    Thunga, Girish
    Shivashankar, K. N.
    Acharya, Leelavathi D.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2023, 17 (07)
  • [32] Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors
    Patel, Bhumika D.
    Bhadada, Shraddha V.
    Ghate, Manjunath D.
    BIOORGANIC CHEMISTRY, 2017, 72 : 345 - 358
  • [33] Exploring Hepatic Safety of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Vildagliptin in a Real-World Setting
    Williams, Rachael
    Kothny, Wolfgang
    Serban, Carmen
    Paldanius, Paivi M.
    Schlienger, Raymond
    DIABETES, 2018, 67
  • [34] CANCER ASSOCIATIONS WITH DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS: A PHARMACOVIGILANCE STUDY OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)
    Teng, C.
    Lu, K.
    VALUE IN HEALTH, 2023, 26 (06) : S174 - S174
  • [35] Serum Level of Soluble CD26/DPP-4 Predicts the Response to Sitagliptin, a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, in Patients With Type 2 Diabetes Inadequately Controlled by Metformin and/or Sulfonylurea
    Aso, Yoshimasa
    Inukai, Toshihiko
    Kasai, Kikuo
    DIABETES, 2012, 61 : A240 - A240
  • [36] Serum levels of pigment epithelium-derived factor (PEDF) are inversely associated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans
    Tahara, Nobuhiro
    Yamagishi, Sho-ichi
    Matsui, Takanori
    Nishino, Yuri
    Honda, Akihiro
    Tahara, Atsuko
    Igata, Sachiyo
    Fukumoto, Yoshihiro
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 184 : 14 - 16
  • [37] Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea
    Aso, Yoshimasa
    Ozeki, Noriyuki
    Terasawa, Tomoko
    Naruse, Rika
    Hara, Kenji
    Suetsugu, Mariko
    Takebayashi, Kohzo
    Shibazaki, Mitsuei
    Haruki, Kohsuke
    Morita, Kimio
    Inukai, Toshihiko
    TRANSLATIONAL RESEARCH, 2012, 159 (01) : 25 - 31
  • [38] COSTS FOR DIABETIC PATIENTS RECEIVING DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS IN US MEDICARE AND COMMERCIAL INSURANCE PLANS
    Rascati, K. L.
    Worley, K.
    Everhart, D.
    Meah, Y.
    VALUE IN HEALTH, 2015, 18 (07) : A601 - A602
  • [39] Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus
    Sasaki T.
    Hiki Y.
    Nagumo S.
    Ikeda R.
    Kimura H.
    Yamashiro K.
    Gojo A.
    Saito T.
    Tomita Y.
    Utsunomiya K.
    Diabetology International, 2010, 1 (2) : 90 - 92
  • [40] Binding to Dipeptidyl Peptidase-4 Determines the Disposition of Linagliptin (BI 1356) - Investigations in DPP-4 Deficient and Wildtype Rats
    Retlich, Silke
    Withopf, Barbara
    Greischel, Andreas
    Staab, Alexander
    Jaehde, Ulrich
    Fuchs, Holger
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2009, 30 (08) : 422 - 436